Landos Biopharma, Inc.
Major Drugs - Blacksburg, VA, US
Landos Biopharma, Inc. Employees
Landos Biopharma, Inc. Senior Management
Landos Biopharma, Inc. Details
Landos Biopharma, Inc (NASDAQ: LABP) is a late-clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases. LANCE has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Lead asset omilancor is a novel gut-restricted small molecule drug candidate for the treatment of ulcerative colitis, Crohn's disease and Eosinophilic Esophagitis that targets the LANCL2 pathway. NX-13 is a novel, gut-restricted small molecule drug candidate for the treatment of inflammatory bowel disease, that targets the NLRX1 pathway. Additional candidates are in development for the treatment of lupus nephritis, rheumatoid arthritis, multiple sclerosis, and diabetes.
Landos Biopharma, Inc. Technologies
Email Providers
Outlook
Domain Name Services
Cloudflare DNS
Other
Microsoft Office 365
Hosting
CloudFlare Hosting